Expert perspectives on polmacoxib monotherapy in the management of osteoarthritis in Indian settings

Manjula S.; Krishna Kumar M.

doi:10.18203/issn.2455-4510.IntJResOrthop20243896

Authors

Manjula S. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
Krishna Kumar M. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20243896

Keywords:

Expert perspectives, Osteoarthritis, Pain management, Polmacoxib

Abstract

Background: Although there were several clinical studies available, there was a dearth of studies among clinicians in actual practice. So, the present survey-based study aimed to gather expert perspectives on the clinical use of polmacoxib monotherapy for the management of osteoarthritis (OA) in routine Indian settings.

Methods: This cross-sectional study employed a 19-item questionnaire to gather expert opinions on managing OA and covered topics such as prescription practices, clinical observations, preferences and experiences with polmacoxib for routine OA management. Descriptive statistics were used to analyze the gathered data.

Results: The study involved 239 participants, with 45% of respondents noting that 31-40% of OA patients are women. According to 65% of the participants, etoricoxib emerged as the most preferred nonsteroidal anti-inflammatory drug (NSAID) in clinical practice. Moreover, 87% of experts recognized the dual cyclooxygenase-2 (COX-2) and carbonic anhydrase (CA) binding properties of polmacoxib as potentially offering superior safety profiles in cardiovascular (CV), renal aspects and Gastrointestinal (GI) tolerability. Around 35% of respondents observed improvements in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), pain reduction, stiffness alleviation and enhanced physical function with polmacoxib.

Conclusions: The study highlighted a significant preference among Indian clinicians for polmacoxib in managing OA, primarily due to its dual COX-2 and CA binding properties that potentially offer better safety profiles in terms of cardiovascular, renal and GI tolerability. Additionally, the observed improvements in pain, stiffness and physical function with polmacoxib underscore its effectiveness as a monotherapy in routine OA management.

Metrics

Metrics Loading ...

References

Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;13;2:16072.

Zhang Y, Jordan JM. Epidemiology of Osteoarthritis. Clin Geriat Med. 2010;1;26(3):355–69.

Hawker GA, Stewart L, French MR, Cibere J, Jordan JM, March L, et al. Understanding the pain experience in hip and knee osteoarthritis–an OARSI/OMERACT initiative. Osteoarthr Cart. 2008;1;16(4):415–22.

GBD 2021 Osteoarthritis collaborators. Global, regional and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021. Lancet Rheumatol. 2023;5(9):508–22.

Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al. US Spending on Personal Health Care and Public Health, 1996-2013. JAMA. 2016;27(24):2627–46.

Woo J, Lau E, Lau CS, Lee P. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services and direct and indirect costs. Arthritis Rheum. 2003;15;49(4):526-34.

World Report on Ageing and Health. World Health Organization. 2015. Available at: https://www.who.int/publications/i/item/9789241565042

Decade of healthy ageing: baseline report. World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/9789240017900

Tong L, Yu H, Huang X, Shen J, Xiao G, Chen L, et al. Current understanding of osteoarthritis pathogenesis and relevant new approaches. Bone Res. 2022;20;10(1):60.

Acharya RN, Patel HM. Prevalence of the Knee Osteoarthritis Risk Factors Among Young Adult Population - An Observational Study. Int J Health Sci Res. 2023;5;13(10):158–63.

Singh A, Das S, Chopra A, Danda D, Paul BJ, March L, et al. Burden of osteoarthritis in India and its states, 1990–2019: findings from the Global Burden of disease study 2019. Osteoarthritis and Cartilage. 2022;1;30(8):1070–8.

Easwaran R, Mistry UK, Bhole M, Peethambaran K. Polmacoxib: A Review of the Newer Non-steroidal Anti-inflammatory Drug in Osteoarthritis. Cureus. 2024;16(4):e58446.

Lee M, Yoo J, Kim JG, Kyung HS, Bin SI, Kang SB, et al. A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis. Clin Orthop Surg. 2017;9(4):439–57.

Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis and Cartilage. 2005;1;13(9):769–81.

Stevens-Lapsley JE, Kohrt WM. Osteoarthritis in women: effects of estrogen, obesity and physical activity. Womens Health (Lond). 2010;6(4):601-15.

Primorac D, Molnar V, Rod E, Jeleč Ž, Čukelj F, Matišić V, et al. Knee Osteoarthritis: A Review of Pathogenesis and State-Of-The-Art Non-Operative Therapeutic Considerations. Genes (Basel). 2020;26;11(8):854.

Loeser RF. The Role of Aging in the Development of Osteoarthritis. Trans Am Clin Climatol Assoc. 2017;128:44–54.

Osteoarthritis. World Health Organization. Available at: www.who.int/news-room/fact-sheets. Accessed on 23 Augus 2024.

Waraich H, Kumar V, Goel A, Singh J. A comparative study to assess the safety and efficacy of etoricoxib versus aceclofenac in osteoarthritis. Int J Basic & Clin Pharmacol. 2018;24;7:2010.

Escudero-Contreras A, Cervantes JVM, Collantes-Estevez E. Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatol. 2007;2(6):545–65.

Sharma JN, Jawad NM. Adverse effects of COX-2 inhibitors. Scient World J. 2005;5(1):927832.